Skip to content

Study · Not a test of the peptide alone · 2026

2 results

Collagen-Enriched Immunomodulatory Hydrogel for Tendon Regeneration.

Patel S, Pan J, Nguyen AP, Howard N, Thankam FG

Gels (Basel, Switzerland)8 Apr 2026

PMID42042155 (opens in a new tab)PMCIDPMC13116411 (opens in a new tab)DOI10.3390/gels12040317 (opens in a new tab)PepBankPUB-42042155
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Rotator cuff tendon injury (RCTI) is aggravated by the pro-inflammatory milieu elicited by TLR4 and TREM1 signaling. Hence, tendon tissue engineering approaches require considerations that address these inflammatory episodes to benefit active regenerative responses. The objective of this study was to engineer and evaluate the immunocompatibility of a tendon-mimetic hydrogel composed of a chitosan-polyvinyl alcohol (PVA) blend incorporated with Collagen-I and to assess LR12 delivery for addressing TREM1-driven inflammation in RCTI management. A chitosan-PVA-HEMA-Acrylic acid (CPHA) hydrogel was synthesized by blending the linear natural polysaccharide chitosan and linear synthetic polymer PVA in an aqueous phase, followed by incorporation and redox chain growth with HEMA using acrylic acid (AA). Interpenetration of Collagen-I in CPHA yielded the CPHA-C hydrogel. CPHA and CPHA-C hydrogels displayed ample surface functional moieties provided by the co-polymers, exhibited excellent porosity as revealed by SEM imaging (28.65 ± 6.85 and 41.56 ± 18.00, respectively, for CPHA and CPHA-C), and were amphiphilic, as evident by contact angle analysis (~70 for CPHA and CPHA-C). Both hydrogels displayed a progressive release profile for the TREM1-inhibitory peptide LR12 for 7 days, whereas the LR12-loaded CPHA hydrogel exhibited increased TREM1 inhibition in LPS-challenged RAW264.7 macrophages. CPHA and CPHA-C hydrogels were immunocompatible and masked the oxidative damage in RAW264.7 macrophages, as evident by decreased levels of mitochondrial superoxide and ROS. Additionally, the CPHA hydrogel displayed an increased TGFβ/TLR4 ratio (0.24), whereas the CPHA-C (-0.52) system showed a decreased ratio upon exposure to tenocytes and macrophages. Overall, the findings highlight the potential of CPHA and CPHA-C hydrogels as candidates for tendon regenerative applications.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Nangibotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Nangibotide.

  1. 01LabNot a test of Nangibotide aloneIn vitro (cells)Mechanism

    In LPS-challenged RAW264.7 macrophages, LR12-loaded CPHA hydrogel increased TREM1 inhibition.

    In plain wordsIn cells challenged with LPS, LR12-loaded CPHA hydrogel increased TREM1 inhibition.

    Peptide
    Nangibotide
    Outcome
    IncreaseTREM1 inhibition
    Study

    n: not reported in source

    LPS-challenged RAW264.7 macrophages
    Outcome group
    Receptor activity and mechanism · Immune and inflammation

    Source sentences

    Summary
    Both hydrogels displayed a progressive release profile for the TREM1-inhibitory peptide LR12 for 7 days, whereas the LR12-loaded CPHA hydrogel exhibited increased TREM1 inhibition in LPS-challenged RAW264.7 macrophages.

    In this study, Nangibotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nangibotide.

  2. 02LabNot a test of Nangibotide aloneIn vitro (cell-free)Pharmacokinetics

    In vitro, CPHA and CPHA-C hydrogels progressively released LR12 for 7 days.

    In plain wordsIn lab tests, both hydrogels progressively released LR12 for 7 days.

    Peptide
    Nangibotide
    Outcome
    Not applicablePeptide release
    Study

    n: not reported in source

    CPHA and CPHA-C hydrogels
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Release duration
    7 days
    CPHA and CPHA-C

    Source sentences

    Summary
    Both hydrogels displayed a progressive release profile for the TREM1-inhibitory peptide LR12 for 7 days, whereas the LR12-loaded CPHA hydrogel exhibited increased TREM1 inhibition in LPS-challenged RAW264.7 macrophages.

    In this study, Nangibotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nangibotide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.